Selected article for: "case study and rapid identification"
Author: Laura Riva; Shuofeng Yuan; Xin Yin; Laura Martin-Sancho; Naoko Matsunaga; Sebastian Burgstaller-Muehlbacher; Lars Pache; Paul P. De Jesus; Mitchell V. Hull; Max Chang; Jasper Fuk-Woo Chan; Jianli Cao; Vincent Kwok-Man Poon; Kristina Herbert; Tu-Trinh Nguyen; Yuan Pu; Courtney Nguyen; Andrey Rubanov; Luis Martinez-Sobrido; Wen-Chun Liu; Lisa Miorin; Kris M. White; Jeffrey R. Johnson; Christopher Benner; Ren Sun; Peter G. Schultz; Andrew Su; Adolfo Garcia-Sastre; Arnab K. Chatterjee; Kwok-Yung Yuen; Sumit K. Chanda
Title: A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals
  • Document date: 2020_4_17
    • ID: 1fgnfh62_3
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04. 16 .044016 doi: bioRxiv preprint most practicable strategies for the rapid identification and deployment of treatments for emerging infectious diseases such as Toward this end, in addition to many anti-immune treatments not addressed in this paper, many investigational clinical trials using repurposed drugs for evaluation of direct antiv.....
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04. 16 .044016 doi: bioRxiv preprint most practicable strategies for the rapid identification and deployment of treatments for emerging infectious diseases such as Toward this end, in addition to many anti-immune treatments not addressed in this paper, many investigational clinical trials using repurposed drugs for evaluation of direct antiviral activity have already been launched. Those include multiple antiviral and antimalarial medicines. Early results of a multicenter trial in China suggested that the antimalarial drug, chloroquine, may limit exacerbation of pneumonia and shorten viral replication and course of disease 15 . A French study that used hydroxychloroquine together with azithromycin reported a significant reduction in viral load in COVID-19 patients when used in combination 16 . However, a sufficiently powered case-control study has not yet been reported, and thus it is unclear if there are therapeutic benefits of chloroquine administration to SARS-CoV-2-infected patients, although several concerns are being raised recently, due to the severe cardiac complications potentially resulting from the use of this treatment in COVID-19 patients 17, 18 .

    Search related documents:
    Co phrase search for related documents
    • anti immune treatment and clinical trial: 1, 2
    • anti immune treatment and infectious disease: 1
    • anti immune treatment and viral load: 1
    • anti immune treatment and viral replication: 1
    • antimalarial antiviral medicine and clinical trial: 1
    • antimalarial drug and azithromycin hydroxychloroquine: 1, 2, 3, 4, 5, 6, 7
    • antimalarial drug and case control: 1, 2, 3
    • antimalarial drug and case control study: 1, 2
    • antimalarial drug and chloroquine administration: 1
    • antimalarial drug and chloroquine antimalarial drug: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
    • antimalarial drug and clinical trial: 1, 2, 3
    • antimalarial drug and infectious disease: 1
    • antimalarial drug and repurposed drug: 1, 2, 3, 4, 5, 6
    • antimalarial drug and significant reduction: 1, 2, 3
    • antimalarial drug and viral load: 1
    • antimalarial drug and viral replication: 1, 2, 3, 4, 5, 6
    • antiviral activity and azithromycin hydroxychloroquine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • antiviral activity and case control: 1, 2
    • antiviral activity and chloroquine administration: 1, 2